Abstract:e21646 Background: Identifying targetable genetic variants may help maximize clinical benefit of non-small cell lung cancer (NSCLC). Here, we retrospectively analyzed the benefit of next-generation sequencing (NGS) for NSCLC in routine clinical practice. Methods: A total of 59 NSCLC patients were enrolled in the study from Jun. 2018 to Dec. 2019. Formalin-fixed paraffin-embedded tissues samples were collected and sequenced by NGS, which detects single-nucleotide variants, small insertions/deletions, rearrangements, and copy-number alterations of either 59 or 1021 tumor related genes. The tumor response was evaluated using RECIST v1.1. Results: The detection rate of targetable variants was 59.32% (35/59), including EGFR mutation 49.15% (29/59), ALK rearrangement 5.08% (3/59), ROS1 rearrangement 1.69% (1/59), BRAF V600E mutation 1.69% (1/59), and ERBB2 mutation 1.69% (1/59). Of 29 patients with EGFR mutations, 5 patients (17.24%) had multiple EGFR mutations, including 2 patients (6.89%) with uncommon mutations. 25patients (86.21%) harbored concurrent mutations that may limit the efficacy of EGFR-TKIs, including EGFR amplification, activation of bypass signaling pathways, TP53 exon8 mutation, BCL2L11 deletion polymorphism, and PI3K-AKT-mTOR and cell cycle gene alterations. Among 25 patients received EGFR-TKIs, TKI effectiveness was evaluated in 18 patients. The disease control rate was 100% and overall response rate was 27.78%. The proportion of patients with TMB-H and/or PD-L1≥1, and targetable variants negative was 33.89% (20/59). Only one patient of this group received immunotherapy with pembrolizumab and achieved SD at the 2 nd month. The proportion of patients with targetable variants negative, TMB-L, and PD-L1 < 1 or unknow patients was 6.78% (4/59), two patients of them left hospital without additional treatment, two patients received chemotherapy and the KRAS mutation present in one of them suggested that he might be resistant to EGFR-TKIs. Conclusions: More than half of NSCLC patients have targetable genetic variants and more than 30% patients have a molecular signature that can be treated with immunotherapy. Compared with immunotherapy, targeted therapy has higher acceptability in real-world. NGS-based genetic testing may have clinical value to predict the effectiveness of targeted therapy and immunotherapy. It can be widely implemented and standardized into clinical use.

Futuro diagnóstico y terapéutico del cáncer de pulmón de células no pequeñas con alteraciones genómicas

Presente y futuro del cáncer de seno HER2 positivo y triple negativo

Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Current role of nanoparticles in the treatment of lung cancer

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

Personalized Medicine: Recent Progress in Cancer Therapy

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

Recent progress in targeted therapy for non-small cell lung cancer

The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Recent advances in lung cancer research: unravelling the future of treatment

Advancements in NSCLC

Results of the First In Situ Implementation of Comprehensive Genomic Profiling

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges